The Incompetence of the MHRA

This one goes out to Kent Woods, CEO of the seriously misinformed & misaligned, MHRA.

I for one expected the outcome of this sham of an investigation to let GSK off the hook. I said so to both the MHRA and on this blog (many times)

What I didn't expect was the complete lack of empathy shown by the MHRA over those poor children that have suffered at the hands of this awful drug. To those that have died as a result of taking Seroxat, your investigation was meant to bring closure to the ones they left behind. Justice was supposed to have been seen to be done. You failed.

Your statement Mr Woods does not warrant publication. It is what patients have been telling the MHRA for years - only to be ignored by yourself and your incompetent team... until now.

I understand the story was leaked to the press Mr Woods. You have a mole in the MHRA it seems? I hope that mole can come forward sometime in the near future.

Are you aware of The Influence of the Pharmaceutical Industry paper Mr Woods? This one was printed in March 2005.

Here's a few extracts to gloss over:

"Very soon after the appointment of the EWG, GSK submitted evidence to the MHRA to support a licensing application for Seroxat use in children. Suspecting a problem, the MHRA requested further data from GSK and, in June 2003, unexpectedly issued a warning to advise against the use of Seroxat in children."

They had the audacity to ask you for a license in children when they knew their drug could cause death in children! That in itself should warrant criminal charges!

"There appears to have been a lack of effective warnings relating to the frequency of withdrawal symptoms experienced with Seroxat. Both the manufacturers, GSK and the regulators, MHRA, claimed they had acted promptly and appropriately in this respect. However, working papers seen by the EWG state that the original licence application recorded Seroxat withdrawal reactions in 30% of patients. The regulators denied this. Three separate reviews conducted by the MCA/CSM in the 1990s were all based on Yellow Card counts, and produced misleadingly low estimates of the risk level"

and this from your Chairman, Alasdair Breckenridge:

"When a drug is licensed and for the first few years until there is good clinical trial evidence, one cannot say what the incidence of an adverse reaction is. You cannot tell that from yellow card reports"

Your system failed and because of this lives were lost. You then waste 4 years investigating what you already knew!

Dr June Raine of the MHRA was told almost 8 years ago by the world's leading expert on SSRi's, Prof. David Healy that Seroxat can cause suicidality. He wrote the day after the Court case in “Cheyenne, Wyoming… found GlaxoSmithKline guilty on several accounts including the count that Paroxetine can cause suicidality, that it specifically did so and contributed to the wrongful death of Don and Rita Schell as well as Deborah and Alyssa Tobin and that the company had been responsible for a failure to test and a failure to warn”.

Why did you not act upon this?

Are you going to now publically acknowledge that Prof. Healy was right?

Are you going to ask why Dr June Raine of the MHRA did not take him seriously?

For years The MCA/MHRA, patient support groups (funded by pharma) and GlaxoSmithKline have publically ridiculed David Healy. He gave you the evidence and you ignored it.

Are both parties pleased with the outcome Mr. Woods? Did you celebrate at the end of this 4 year farce?

Children have died, families have been ripped apart, GP's have prescribed 'off label' and YOU knew.

Would you like to make an official statement to Stephanie Gatchell Mr Woods? Do you even know who she is Mr Woods?

Are you even bothered Mr Woods?

So the investigation is over. GSK did wrong and are let of the hook. What now Mr Woods?

Have you had a chance to read through the Glenmullen report yet Mr Woods? I sent it to the MHRA the day it was released. It clearly shows an increased rate of suicidality in ALL patients NOT just children. 9 pages were missing from this report. You may want to ask Sen Grassley for these, he wrote to GSK and demanded them! Again, someone else doing the job of the regulator.

Am I right to suggest that this will be investigated too?

Will you be liasing with GlaxoSmithKline over this?

You have failed on a grand scale. You failed as the MCA with the MMR/Autism debacle. You also failed with the Myodil debacle. You would have thought then that lessons would have been learned. But here we are once more. A catalogue of errors, evidence that you knew about the dangers almost 8 years ago but did nothing.

I want you to go home tonight Mr.Woods and light a candle. As it burns I want you to look deep inside the flame. Search inside for your conscience. You and your regulators have once again let down the British public. You have once again stood by and let children suffer, as you did with the MMR jab. Your close ties with the industry has never been so apparent as what it is today following the results of your sham of an investigation.

I would like to take this opportunity to offer my sincere condolences to all those family members who have had to bury/cremate their children because of GlaxoSmithKline's Seroxat and because the Medicine Regulator here in the UK refused to listen to patients and the World's leading expert.

I'm absolutely livid.

God only knows what the bereaved families are going through today!

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

I urge the NSPCC to become involved in this Seroxat debacle

----- Original Message -----
From: fiddaman
To: Helpline@nspcc.org.uk
Sent: Thursday, March 06, 2008 2:41 PM
Subject: Seroxat
Dear NSPCC,

I am sure you are aware of the MHRA's four year investigation into pharmaceutical giants, GlaxoSmithKline.

Basically, the antidepressant, Seroxat has been prescribed to children throughout the UK 'off label'.

The MHRA's sham of an investigation found GlaxoSmithKline guilty of witholding vital evidence, which in effect could have saved the lives of many of the children who have committed suicide as a result of taking this drug.

Now forgive me if I am wrong but isn't this woeful neglect/abuse of children?

I would very much appreciate your feedback on this matter because somebody needs to hold their hands up here and take some form of responsibilty.

Kent Woods is CEO of the MHRA.

He, surely is responsible for allowing this to happen.

Apparently GlaxoSmithKline cannot be prosecuted for killing those poor children.

Somebody HAS to take responsibility and accept the blame.

I urge the NSPCC to become involved in this and use its voice. This is murder on a very large scale and has been investigated by a bunch of incompetent morons who incidently are funded by the very same people they investigated!

I await your reply and hope we can work together on this to bring those responsible to justice.

Yours sincerely

Bob Fiddaman

Seroxat Sufferers
http://fiddaman.blogspot.com

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

CORPORATE MURDER BY GLAXOSMITHKLINE?

The following rant contains language of an adult nature


They have quite literally gotten away with murder.

They withheld vital clinical trial results back from the regulators, results that could possibly have saved lives.

They chose not to release this data because it would have dramatically hit sales of Seroxat, they chose not to release this data because under law, a fucked up law at that, they were allowed to.

4 years investigating GlaxoSmithKline - yes they have been found to be negligent, yes they held back vital evidence that could have saved lives, yes they sat back and allowed GP's to prescribe this horrendous drug to children (albeit off label)

The MHRA were told about this - it took them 4 long years to come to the conclusion that GlaxoSmithKline actually were holding back evidence.

I have been telling Kent Woods and his bunch of fucking merry men this for years.

Why didn't the MHRA Chairman, Alasdair Breckenridge inform Woods & Co that something underhand was going on at GlaxoSmithKline, after all HE WAS EMPLOYED BY THEM!

Why didn't Head of Licensing at the MHRA, Dr Ian Hudson, Tell Woods & Co that something underhand was going on at GlaxoSmithKline, HE WAS ALSO EMPLOYED BY THEM!

Now ladies and gentlemen at the MHRA. How long are you going to take apologising to all those children whose lives have been ruined by this bastard drug? Or apologising to the parents who have lost children because of this bastard drug?

From your investigation, you have stated that you won't/can't criminally charge GlaxoSmithKline - so maybe you should take full responsibity? You did after all turn a blind eye and allow off label prescribing of this drug didn't you?

I must be psychic, I kind of predicted the result of this sham of an investigation.

WHEN ARE THE MHRA GOING TO ACTUALLY FUCKING LISTEN TO THE PATIENTS?

Angry?

You fucking better beleive I am!

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

Want to make a complaint against GSK and/or the MHRA?

Try the NSPCC (The National Society for the Prevention of Cruelty to Children)

I will be lodging a formal complaint later today, provided they ain't funded by GSK that is!

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

MHRA to Let GSK off the Hook

Cast you mind back to BBC TV's Panorama. Shelly Jofre asked MHRA Chairman if criminal charges may be brought against GlaxoSmithKline - he answered 'that is a possibility'

Well, it seems that Breckenridge was either misinformed or it was just a lie.

Here is a breaking news story from todays Guardian

A major tightening of the law governing the oversight of drugs companies will be announced today when the government says GlaxoSmithKline delayed informing the authorities that a controversial drug increased the likelihood of suicide among teenagers.

The health minister Dawn Primarolo will tell MPs that new legislation will be introduced by the end of the year to ensure drugs companies pass on results of clinical trials as soon as the alarm is raised about one of their medicines.

The government is to intervene after a four-year investigation by the drug regulatory body into the way GSK withheld the full results of their trials of the antidepressant Seroxat on children

The trial data, which was finally handed to the Medicines and Healthcare Regulatory Authority (MHRA) in May 2003, identified two problems of which the company had been aware as early as 1998:

A higher risk of suicidal behaviour among under 18s using Seroxat rather than a placebo.

Seroxat was ineffective in dealing with depressive illness among under 18s.

Primarolo will announce that GSK should have told the MHRA earlier than it did about the results. But GSK will not face criminal prosecutions, she will say, because the legislation in this area is insufficiently clear on whether and when drugs companies should inform the regulator.

The minister will announce that new legislation will be introduced by the end of the year placing a greater obligation on companies to disclose results of trials.

The MHRA's investigation asked whether GSK had informed the regulatory body in reasonable time. It shows that the drug company had the information about the potentially suicidal effects of Seroxat and concludes that GSK should have informed the MHRA earlier. However, it finds that the company acted within the letter of the law by withholding data that would have shown up a problem. The failure to take stronger action against GSK will anger the many critics of the regulatory body, who say it is not up to the job of policing the pharmaceutical industry.

Patients and some doctors have been urging a tough line against GSK ever since the MHRA suddenly announced, in June 2003, that doctors must not give Seroxat to children and under 18s.

The agency said it was acting within two weeks of being given the full set of data from trials of Seroxat in children. The statistics contained in those results showed that the drug was no better than a placebo in alleviating depression in children and that those on the drug were more likely to develop suicidal tendencies than those on placebo. In one of the trials, 6.5% of those taking Seroxat became suicidal compared with 1.1% in the placebo group.

A leaked internal document from GSK, dated to 1998, said the company would have to "effectively manage the dissemination of these data in order to minimise any potential negative impact".

In the United States, GSK was sued by the New York state attorney general, Eliot Spitzer, and settled for $2.5m (£1.25m) and an agreement to publish all its trial results - negative or positive - on a publicly available database.

Critics have called for big changes to the MHRA. In its report into the influence of the pharmaceutical industry, the Commons' health select committee expressed concern that the MHRA did not get all the information it needed from manufacturers before it licensed drugs. It called for a new regime of random audits of the raw trial data collected by companies and for more staff to be employed.

GSK has always completely rejected allegations that it improperly withheld data on the drug. It said Seroxat had never been approved by EU or US regulators as a medicine for those under 18, and that the company had therefore never marketed the drug for that age section. It also said its trial results had been submitted to regulators and were presented publicly in journals and on its website.


And they have the audacity to call themselves regulators!

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

More on the MHRA and Herbal Remedies

Some classic MHRA quotes on their recent (probably Pharma instructioned) crackdown on herbal remedies.

Source: StaffNurse.com

"continuing evidence of bad and dangerous practices across parts of the unlicensed herbal sector"

"extremely dangerous advice to patients"

"This is a serious problem that is indicative of low grade manufacturing standards and in some cases a deliberate intention to deceive the public,"


Isn't that last quote an absolute beauty?

Deceive the public?

And these are the people that regulate the drugs we take.

How's the investigation going on Kent? You plan to drag it out to five, six or will it be seven years?

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

MHRA Herbal Priority

Well the MHRA seem to be getting their priorities in order by 'warning the public to be vigilant' over bad and dangerous practices across parts of the unlicensed herbal sector.

The MHRA found reports of suspected adverse drug reactions (Wow, you mean they actually listen to patients?)

You can read more here

But I would like to point out their case studies:

Two suspected adverse drug reactions reports have been received in association with in a multi-constituent Ayurvedic remedy. Yes TWO adverse drug reactions.

A man collapsed after consuming a product called Tian Li, which claimed to give sexual enhancement. Whilst no permanent ill health was suffered by the consumer, the result of our analysis showed the presence of hydroxyhomosildenafil at a level of 39.6mg per capsule and tadalafil at 14.4mg per capsule. Yes ONE man collapsed.

A woman who purchased a slimming product called Li Da Dai. She used this product for three days and felt a bit weak and vomited. It gets better doesn't it. ONE woman vomited.

I've saved the best til last...


The Agency recently received a complaint from a clinician who has expressed concern that an Ayurvedic practitioner had advised a patient not to take his medicine for schizophrenia and instead go to India for other treatments. Thus putting Pharma out of pocket no doubt?

Now, have the MHRA received more than one report of anyone vomiting on Seroxat?

Has any patient ever filled in a yellow card and told them about electrifying zaps jolting through their body whilst withdrawing from Seroxat? Hey don't worry, they are on the case, ONE man collapsed whilst taking a product called Tian Li so I'm sure they will get around to the reports of electric zaps soon enough.

TWO suspected adverse drug reactions to an Ayurvedic remedy. Phew! not one but TWO!

Of course they have never had any reports of adverse drug reactions from patients taking Seroxat have they?

Who are going to lose out if Herbal Remedies become popular?

Pharma!

Need I say anymore

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

Benefits of Seroxat? DoH answer... or do they?

Some of you know I've been hounding the Department of Health for an answer for over a month now. I asked them one simple question: What is the benefit of Seroxat?

In classic MHRA/GlaxoSmithKline style they answer me - totally avoiding the question:

----- Original Message -----
From: dhmail@dh.gsi.gov.uk
To: fiddaman64
Sent: Tuesday, March 04, 2008 2:29 PM
Subject: Response to your Query : - Ref:DE00000283875 - Anti-depressants

Our ref: REDACTED

Dear Mr Fiddaman,

Thank you for your email of 26 February to the Department of Health about a recently published study on antidepressants. New guidance on the treatment of depression will be issued by National Institute for Health and Clinical Excellence later in the year, and this new study will be considered as the guidance is prepared. Until then, the message to patients and doctors remains the same - antidepressants are an appropriate treatment for moderate or severe depression.

The Department is, however, expanding the availability of psychological therapies as an alternative to drugs with extra investment and plans to train an extra 3,600 psychological therapists. The evidence shows that these therapies are effective and often preferred by patients.

I hope this reply is helpful.

Yours sincerely,
Edward Corbett
Customer Service Centre.
----


I hope this reply is helpful?

Yup, about as helpful as sending me a man with no arms to groom my dog!

So, what is the benefit of Seroxat? I may go and ask the brick wall at the foot of my garden!

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

Antidepressant/Placebo = Shrink/Counsellor?

So antidepressants for people suffering with mild to moderate depression are about as effective as taking a placebo?

Basically then, are we to beleive that an antidepressant (or placebo) is merely doing the work of a shrink/counsellor?

In essence, this seems to be the gist of things doesn't it? Or have I got it all wrong?

Take an antidepressant for mild to moderate depression and the patient 'may' feel they are getting better.

Go talk to a shrink/counsellor and the patient (over time) will feel they are getting better.

Take a placebo for mild to moderate depression and the patient 'may' feel they are getting better.

I'm surprised there has been no entrepreneur who has latched onto this very lucrative market.

Think about it. A drug that claims to cure your depression but really it's a sweet - the patient, obviously does not know this.

You could get past the FDA/MHRA with the ingredients of the drug as both regulators seem pretty useless when it comes to regulating the drugs we take anyway.

If there were only such a market eh?

It seems Pharma have the stranglehold on this too because basically their drugs to cure depression are placebos with chemicals.

The only benefit seems to be long term adverse reactions. Maybe we should thank Pharma for showing us what addiction feels like, giving us sleepless nights, electric zaps jolting through our bodies, heightened aggression, feelings of suicide and homicide plus a host of other reactions that accompany these drugs?

End of the day, Pharma and the regulators have lied to us all. For years they have touted 'The benefits far outweigh the risks' line.

Their studies are akin to giving a small child a gun, leaving the child in a room and intermittently allowing a group of people into that room. Some of the people want to show the child love, others want to kill the child. The child does not know the good from the bad so shoots and kills 3 random people. Luckily for the child, he kills one child murderer - Phew! these guns can come in pretty handy, it saved the child from being murdered. Let's publish the results, it don't matter about the two innocent people that the child killed... at the end of the day, the gun saved this child's life!

An extreme analogy, I agree, but one that is the basis of clinical trials.

Or am I wrong?

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

Lapdap. GlaxoSmithKline and The MHRA

The connection between GlaxoSmithKline's Lapdap and MHRA Chairman Alisdair Breckenridge.

GlaxoSmithKline Plc is scrapping two malaria drugs that may cause anemia, dealing a blow to the global fight against the killer disease.

Europe's biggest drugmaker said on Friday it was pulling Lapdap from the market in Kenya -- the only place where it has recently been sold -- and stopping development of a second experimental compound called Dacart.

Both medicines have been linked to reductions in hemoglobin levels in patients with a hereditary enzyme disorder that affects 10 to 25 percent of Africans. Low hemoglobin can lead to anemia which in severe cases may require a blood transfusion.

Lets first start with GlaxoSmithKline and move on to Breckenridge later.

In 2002, talking of Lapdap, GlaxoSmithKline said:

There has been progress in malaria too. In October 2002, we submitted a regulatory application to the UK Medicines Control Agency (MCA) for Lapdap (chlorproguanil/dapsone) for the treatment of the most life threatening type of the malaria. MCA approval will be an important step in making Lapdap available across Africa, where there is great need for new malaria treatments.

Lapdap results from a successful partnership between GSK, the World Health Organization, the University of Liverpool, the London School of Hygiene & Tropical Medicine, and the UK Department for International Development (DFID) This is the first such product development to be directly sponsored by DFID.

The University of Liverpool? Hmmm

Professor Sir Alasdair Breckenridge, CBE, was most recently Professor of Clinical Pharmacology at the University of Liverpool.

He has been Chair of the Committee on Safety of Medicines (CSM) since 1999, a role which he relinquished when he became chair of the MHRA on its creation in April 2003.

The University of Liverpool has capitalised on 15 years' research by initiating a Public Private Partnership to turn promising lab results into an affordable anti-malarial treatment which can combat drug resistance in Africa.

In the 2003 University of Liverpool Annual Report there is a full page spread 'bigging up' Lapdap. The blurb reads:

Fighting malaria: Professor Peter Winstanley has led the development of a new low-cost anti-malarial drug LapdapTM, designed for sub-Saharan Africa where ‘Plasmodium falciparum’ malaria kills one to two million people every year.

It continues...

GLAXOSMITHKLINE (GSK) WILL MARKET THE AFFORDABLE NEW DRUG.
LAPDAP HAS BEEN DEVELOPED THROUGH A UNIQUE PUBLIC-PRIVATE PARTNERSHIP BETWEEN THE UNIVERSITY, THE WORLD HEALTH ORGANISATION, GSK, THE GOVERNMENT’S DEPARTMENT FOR INTERNATIONAL DEVELOPMENT (DFID), THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE AND THE LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, WITH GRANT SUPPORT FROM THE WELLCOME TRUST.

Breckenridge, along with Peter Winstanley, Stephen Ward, Robert Snow, wrote a paper entitled: Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

In it, they wrote:

The burden of falciparum malaria remains as great as ever, and, as has probably always been the case, it is carried mainly by tropical Africa. Of the various means available for the control of malaria, the use of effective drugs remains the most important and is likely to remain so for a considerable time to come.

And what would that 'effective drug' be?

Lapdap - The outcome of a successful partnership between GlaxoSmithKline and The University of Liverpool - Coincidently where Sir Alisdair Breckenridge was Professor of Clinical Pharmacology.

Not so successful now Lapdap has been linked to reductions in hemoglobin levels in patients which can lead to anemia!

Alisdair Breckenridge is currently Chairman of the MHRA. The regulator that 'regulates' the drugs you and I take.

He has also defended Seroxat

Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

West Belfast - 40% on anti-depressants

This article pretty much sums up the stranglehold pharmaceutical companies have on people and doctors. In the case of GlaxoSmithKline's Seroxat, it is my belief THEY KNEW it was addictive. THEY KNEW patients would have extreme difficulty coming off it. THEY KNEW patients would have to keep taking it to feed their addiction. THEY STILL KNOW. They, along with The MHRA, still DENY.

Fid


Source: Andersonstown News

By Ciarán Barnes

Up to 40 per cent of adults in some parts of West Belfast are popping ‘happy’ pills to cope with depression.

Areas like Ballymurphy and the lower Falls are the worst hit, with many now addicted to strong medicines.

News of the frightening addiction levels came on the same day a study found that anti-depressants have little clinical effect on patients. The University of Hull study tested popular drugs like Prozac and Seroxat.

Thousands of West Belfast residents are prescribed these drugs to combat depression. Although they are packaged as being ‘non-addictive’, many users find it impossible to get through the day without popping at least one pill.

Under new health reforms based on the University of Hull findings, anti-depressant users could be stripped off their drugs and made to undergo therapy treatment instead.

This would present doctors with a nightmare scenario, as many of their patients would find it impossible to get through the day without a Prozac or Seroxat fix. Leading West Belfast pharmacist Terry Maguire said the study would have huge implications in West Belfast.

However, he cautioned against taking its findings as verbatim, insisting more tests need to be done.

Terry said: “Every healthcare professional needs to look closely at the details of the study. More consideration needs to be given because it could have huge implications.”A senior medical source expanded on this, revealing that up to 40 per cent of people in the poorest parts of West Belfast are on anti-depressants.

“It would create huge difficulties if doctors all of a sudden stopped prescribing these pills,” said one healthcare professional.

“Patients who are on them, many of whom are addicted to them, would not know what to do. They just wouldn’t be able to get their day in. Look at Ballymurphy and the lower Falls, I’d say 40 per cent of adults are taking some type of anti-depressant. ”The medical source explained that doctors prefer prescribing Prozac and Seroxat because they are not classed as addictive drugs."

“It’s easier for a doctor to give someone Prozac than Diazepam because it’s not classed as addictive,” he added.

“But there are thousands of people who aren’t really depressed taking the drug. They’ve been prescribed it because of a fear in doctors that the patient might do something drastic if they don’t get what they are asking for.

“Then when the patient comes off Prozac they start to feel low so the doctor has no choice but to prescribe it again. It’s a vicious circle that needs to be examined quite urgently.”

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON

Chemically-Induced Suicide: 80% of Suicide Victims Took Antidepressant Drugs

Chemically-Induced Suicide: 80% of Suicide Victims Took Antidepressant Drugs

A Swedish writer has accused the National Board of Health and Welfare (NBHW) of covering up evidence suggesting a connection between psychiatric drugs and suicide. Under a recent law, Swedish health-care providers must fill out reports on all suicides committed by patients under their care or within four weeks of a health care visit. The reports are then sent to the NBHW, which compiles and analyzes them.

FULL STORY HERE

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON